It is important for Amgros to be at the leading edge of the rapid developments in the global pharmaceuticals market. Therefore, we are systematically monitoring individual pharmaceuticals and their positions in what we call the pharmaceutical lifecycle, which overall comprises six stages:
Stage 1 is where a brand-new patented pharmaceutical is introduced on the market. At this stage, Amgros can negotiate a price lower than the supplier's list price. Read more about this process under New pharmaceuticals.
At stages 2-4, other similar pharmaceuticals with the same effect, but another primary ingredient, enter the market. If these pharmaceuticals are approved for the same treatment, there will be analogue competition.
At stages 4-6, the patent for the pharmaceutical has expired, and there will be generic competition. Competition can be very intense during these stages, and usually there will be a strong downward pressure on prices.
If a new medicine is to be considered as a standard treatment at Danish public hospitals, the Danish Medicines Council has to assess and recommend it first.READ MORE
When the Danish Medicines Council is to assess several pharmaceuticals within the same therapeutic area, it prepares treatment guidelines.READ MORE
When the patent on a pharmaceutical expires, and generic or biosimilar alternatives enter the market, Amgros’ task is to ensure the widest possible competition.READ MORE
Negotiation of prices
After the Danish Medicines Council has completed a health economic assessment of a new medicine, Amgros negotiates the price of the medicine.READ MORE